References:
- Bateman BT, et al. 2015. Statins and congenital malformations: cohort study. BMJ. 17;350:h1035.
- Cleary KL, et al. 2014. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol; 38(8):523-7.
- Constantine MM, Cleary K. 2013. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol; 121(2 0 1).
- Kazmin A, et al. 2007. Risk of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can; 29(11):906.
- Kusters DM, et al. 2012. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther; 10(3):363-78.
- Maierean SM, et al. 2018. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert Opin Investig Drugs; 27(5):427-435.
- McElhatton P. 2005. Preliminary data on exposure to statins during pregnancy. Reprod Toxicol; 20:471-2.
- Morton S, Thangaratinam S. 2013. Statins in pregnancy. Curr Opin Obstet Gynecol; 25(6):433-40.
- Ofori B, et al. 2007. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol; 64(4):496-509.
- Taguchi N, et al. 2008. Prenatal exposure to HMG CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol; 26(2):175-7.
- Winterfeld U, et al. 2013. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG; 120(4):463-71.
- Wolfgang P, et al. 2004. Pregnancy outcome after medication with HMG-CoA reductase inhibitors in the first trimester. Reprod Toxicol; 19:254-5.
